Global Health Sector Shake-ups and Innovations
Recent developments in the health sector include Trump's spending bill impact on Medicaid, Waters Corp's acquisition of a Becton unit, and FDA concerns over GSK's cancer drug. Additional highlights cover Moroccan Vicenne's IPO oversubscription, GSK's RSV vaccine expansion, and CSL's R&D restructuring plans.
In recent health news, President Donald Trump's spending bill is poised to increase administrative costs for leading insurers like UnitedHealthcare, leading to reduced Medicaid coverage, industry experts predict. The bill's impact may drive insurers to focus on existing markets to retain healthier members.
Meanwhile, Waters Corp has announced its intention to acquire a diagnostics unit from Becton Dickinson in a stock-and-cash deal valued at $17.5 billion. This move seeks to expand Waters' footprint in clinical and diagnostic applications while Becton shifts focus towards core medtech areas for greater pricing power and manufacturing strength.
In drug regulation news, FDA staff have raised alarms over potential eye safety risks linked to GSK's blood cancer medication Blenrep. Concerns focus on the drug's safety when used in combination therapies, with questions about its benefit-risk profile still under scrutiny.
(With inputs from agencies.)
ALSO READ
Global Headlines: From Eye Safety in Cancer Drugs to IPO Surges
Data Dilemma: ICE and Medicaid's Controversial Agreement
Privacy Concerns Emerge as Medicaid Data Shared with ICE
Immigration Authorities Access Medicaid Data: Privacy Concerns Raised
Agreement gives US immigration authorities access to Medicaid records, including 79 million addresses and ethnicities, reports AP.
Google News